We screened differentially expressed lncRNAs through The Cancer Genome Atlas (TCGA) database and identified molecule LYRM4-AS1, which was thought to be a significant high-risk lncRNA in survival for glioma patients (Ouyang et al., 2022). Here, LYRM4 is linked to central nervous system cancer.